➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Colorcon
Medtronic
Boehringer Ingelheim
Merck

Last Updated: October 21, 2020

DrugPatentWatch Database Preview

Details for Patent: 7,932,241

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,932,241 protect, and when does it expire?

Patent 7,932,241 protects ZOMETA and RECLAST and is included in two NDAs.

Protection for RECLAST has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-six patent family members in twenty-two countries.

Summary for Patent: 7,932,241
Title:Pharmaceutical products comprising bisphosphonates
Abstract: A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of a ready to use infusion solution, for administration of the bisphosphonate to a patient in need of bisphosphonate treatment.
Inventor(s): Glausch; Alexandra (Weil am Rhein, DE), Loffler; Rolf (Freiburg, DE), Sigg; Juergen (Loerrach, DE)
Assignee: Novartis AG (Basel, CH)
Application Number:10/570,339
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,932,241
Patent Claim Types:
see list of patent claims
Formulation; Compound; Process;

Drugs Protected by US Patent 7,932,241

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis ZOMETA zoledronic acid INJECTABLE;INTRAVENOUS 021223-003 Jun 17, 2011 AP RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Novartis RECLAST zoledronic acid INJECTABLE;INTRAVENOUS 021817-001 Apr 16, 2007 AP RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,932,241

PCT Information
PCT FiledSeptember 17, 2004PCT Application Number:PCT/EP2004/010470
PCT Publication Date:March 24, 2005PCT Publication Number: WO2005/025551

International Family Members for US Patent 7,932,241

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 045670   Start Trial
Australia 2004271731   Start Trial
Brazil PI0414562   Start Trial
Canada 2536206   Start Trial
China 1852739   Start Trial
Colombia 5680461   Start Trial
Ecuador SP066419   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Medtronic
AstraZeneca
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.